Published June 14, 2021 | Version v1
Journal article

Chk1 suppression leads to a reduction in the enhanced radiation-induced invasive capability on breast cancer cells

  • 1. Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Suita, Osaka (Japan)
  • 2. Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka (Japan)

Description

Radiation therapy is generally effective for treating breast cancers. However, approximately 30% of patients with breast cancer experience occasional post-treatment local and distant metastasis. Low-dose (0.5 Gy) irradiation is a risk factor that promotes the invasiveness of breast cancers. Although an inhibitor of checkpoint kinase 1 (Chk1) suppresses the growth and motility of breast cancer cell lines, no study has investigated the effects of the combined use of a Chk1 inhibitor and radiation on cancer metastasis. Here, we addressed this question by treating the human breast cancer cell line MDA-MB-231 (in vitro) and mouse mammary tumor cell line 4 T1 (in vitro and in vivo) with γ-irradiation and the Chk1 inhibitor PD407824. Low-dose γ-irradiation promoted invasiveness, which was suppressed by PD407824. Comprehensive gene expression analysis revealed that low-dose γ-irradiation upregulated the mRNA and protein levels of S100A4, the both of which were downregulated by PD407824. We conclude that PD407824 suppresses the expression of S100A4. As the result, γ-irradiation-induced cell invasiveness were inhibited.

Availability note (English)

Available from http://dx.doi.org/10.1093/jrr/rrab049; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438270

Additional details

Publishing Information

Journal Title
Journal of Radiation Research
Journal Volume
62
Journal Issue
5
Journal Page Range
p. 764-772
ISSN
0449-3060

Optional Information

Copyright
Copyright (c) The Author(s) 2021. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology
Notes
PMCID: PMC8438270; PMID: 34124754; PMID: 34124754; PUBLISHER-ID: rrab049; OAI: oai:pubmedcentral.nih.gov:8438270